NCT00403494
Intermittent Claudication
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
All
40 Years to 80 Years
No
Placebo, Sapropterin Dihydrochloride
Phase 2
Interventional
190
2006-12
2021-01-07
Scottsdale, Arizona, United States
Sacramento, California, United States
San Diego, California, United States
Santa Ana, California, United States
Santa Rosa, California, United States
Clearwater, Florida, United States
Jacksonville, Florida, United States
Conyers, Georgia, United States
Indianapolis, Indiana, United States
Auburn, Maine, United States
Charlotte, North Carolina, United States
Portland, Oregon, United States
Knoxville, Tennessee, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Buenos Aires, , Argentina
Corrientes, , Argentina
Santa Fe, , Argentina
1. Resting ankle-brachial index (ABI) 1.3 (indicating non-compressible vessels), vascular etiology documented by toe-brachial index (TBI) < 0.7 in at least one leg
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields